(Q39562583)

13 September 2017

title

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts (English)

1 reference

13 September 2017

1 reference

1 reference

Pooja Hingorani

1

1 reference

13 September 2017

Wendong Zhang

2

1 reference

13 September 2017

Juan Lin

3

1 reference

13 September 2017

Laibin Liu

4

1 reference

13 September 2017

Chandan Guha

5

1 reference

13 September 2017

E Anders Kolb

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

8 November 2010

1 reference

13 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

13 September 2017

volume

117

1 reference

13 September 2017

issue

8

1 reference

13 September 2017

page(s)

1764-1774

1 reference

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Reovirus as an oncolytic agent against experimental human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

The preferential cytotoxicity of reovirus for certain transformed cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25741

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25741

1 reference

13 September 2017

1 reference